UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study

Tabberer, M; Jones, CE; Kilbride, S; Halpin, DMG; Lomas, DA; Pascoe, S; Singh, D; ... Lipson, DA; + view all (2020) Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. Advances in Therapy 10.1007/s12325-020-01409-8. (In press). Green open access

[thumbnail of Tabberer2020_Article_Single-InhalerTripleTherapyAnd.pdf]
Preview
Text
Tabberer2020_Article_Single-InhalerTripleTherapyAnd.pdf - Published version

Download (1MB) | Preview

Abstract

INTRODUCTION: The phase 3 InforMing the PAthway of COPD (chronic obstructive pulmonary disease) Treatment (IMPACT) trial, single-inhaler therapy with fluticasone furoate (FF) 100 μg, umeclidinium (UMEC) 62.5 μg, and vilanterol (VI) 25 μg demonstrated a reduction in the rate of moderate or severe exacerbations compared with FF/VI or UMEC/VI in patients with symptomatic COPD at risk of exacerbations. This article reports additional evidence of improvements in symptoms and health-related quality of life (HRQoL) with FF/UMEC/VI compared with either FF/VI or UMEC/VI from the IMPACT study. METHODS: Patient-reported HRQoL assessments and symptom measures included as pre-specified IMPACT end points were the St George's Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), and Baseline Dyspnea Index (BDI) as the anchor for the Transitional Dyspnea Index (TDI) focal score (BDI/TDI) in a subset of patients enrolled at study sites in North America and Europe. Change from baseline was assessed at weeks 4, 28, and 52. RESULTS: The intent-to-treat population included 10,355 patients (TDI population: 5058 patients). Clinically meaningful improvements in SGRQ total score between baseline and week 52 favored FF/UMEC/VI over FF/VI (- 1.8 units, p < 0.001) and UMEC/VI (- 1.8 units, p < 0.001). Similar improvements in the CAT and TDI focal score were also observed with FF/UMEC/VI versus FF/VI or UMEC/VI. CONCLUSIONS: This study demonstrates that in patients with symptomatic COPD at risk of exacerbations, once-daily FF/UMEC/VI, compared with FF/VI or UMEC/VI, improves patient-perceived HRQoL and symptoms. TRIAL REGISTRATION NUMBER: NCT02164513.

Type: Article
Title: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1007/s12325-020-01409-8
Publisher version: https://doi.org/10.1007/s12325-020-01409-8
Language: English
Additional information: This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Keywords: COPD, Exacerbations, Health-related quality of life, IMPACT trial, Patient-reported outcomes, Single-inhaler triple therapy
UCL classification: UCL
UCL > Provost and Vice Provost Offices > VP: Health
URI: https://discovery.ucl.ac.uk/id/eprint/10105604
Downloads since deposit
22Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item